DE602005020646D1 - Screening-verfahren - Google Patents

Screening-verfahren

Info

Publication number
DE602005020646D1
DE602005020646D1 DE602005020646T DE602005020646T DE602005020646D1 DE 602005020646 D1 DE602005020646 D1 DE 602005020646D1 DE 602005020646 T DE602005020646 T DE 602005020646T DE 602005020646 T DE602005020646 T DE 602005020646T DE 602005020646 D1 DE602005020646 D1 DE 602005020646D1
Authority
DE
Germany
Prior art keywords
salt
screening
protein
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005020646T
Other languages
English (en)
Inventor
Yasuaki Ito
Kazunori Nishi
Shoichi Ohkubo
Masataka Harada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE602005020646D1 publication Critical patent/DE602005020646D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
DE602005020646T 2004-08-30 2005-08-29 Screening-verfahren Active DE602005020646D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004250786 2004-08-30
PCT/JP2005/016169 WO2006025551A1 (ja) 2004-08-30 2005-08-29 スクリーニング方法

Publications (1)

Publication Number Publication Date
DE602005020646D1 true DE602005020646D1 (de) 2010-05-27

Family

ID=36000195

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005020646T Active DE602005020646D1 (de) 2004-08-30 2005-08-29 Screening-verfahren

Country Status (6)

Country Link
US (1) US7892755B2 (de)
EP (1) EP1788390B1 (de)
JP (1) JP4772684B2 (de)
AT (1) ATE464564T1 (de)
DE (1) DE602005020646D1 (de)
WO (1) WO2006025551A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120022116A1 (en) * 2010-07-20 2012-01-26 Huayun Deng Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
CN109929805A (zh) * 2017-12-15 2019-06-25 中国科学院大连化学物理研究所 鼠源gpr35高通量筛选模型的构建方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2832726B2 (ja) * 1989-08-03 1998-12-09 日本ケミファ株式会社 消化管運動抑制用医薬組成物
CA2219605C (en) * 1996-10-31 2002-02-05 Deepa Ashok Khambe Method of stimulating gastrointestinal motility with ellagic acid
US20020168720A1 (en) * 1997-02-06 2002-11-14 Takeda Chemical Industries Ltd. G protein coupled receptor proteins, their production and use
US7119190B2 (en) * 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
DE19728326A1 (de) 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
EP1043395B1 (de) 1997-12-26 2008-12-03 Banyu Pharmaceutical Co., Ltd. Neue g-protein gekoppelte rezeptorproteine
EP1084142A4 (de) 1998-06-11 2005-01-19 Smithkline Beecham Corp Gpr35a-rezeptor
AU2398501A (en) * 1999-12-20 2001-07-03 Banyu Pharmaceutical Co., Ltd. Novel guanosine triphosphate-binding protein-coupled receptor protein, bg26
EP1312374B1 (de) * 2000-08-01 2008-09-10 Oryza Oil & Fat Chemical Co., Ltd Nachtkerzensamenextrakte als inhibitoren der zuckerabsorption und deren herstellungsprozess
WO2002068600A2 (en) * 2001-02-26 2002-09-06 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
EP1581648A2 (de) * 2002-09-09 2005-10-05 Nura, Inc. G-protein-gekoppelte rezeptoren und deren verwendung
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20070048740A1 (en) * 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
EP1447413A3 (de) * 2003-02-14 2006-01-04 Research Association for Biotechnology Vollständige humane cDNA
EP1522858A1 (de) * 2003-10-10 2005-04-13 Jean-Christophe Roegel Methoden für Selektion von Verbindungen unter Verwendung von Antikörpern mit Aktivität als Agonist, Antagonist oder allosterischen Modulatoren
WO2005059546A2 (en) 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)

Also Published As

Publication number Publication date
WO2006025551A1 (ja) 2006-03-09
US20080103215A1 (en) 2008-05-01
JP4772684B2 (ja) 2011-09-14
JPWO2006025551A1 (ja) 2008-05-08
EP1788390A1 (de) 2007-05-23
EP1788390A4 (de) 2008-02-13
EP1788390B1 (de) 2010-04-14
US7892755B2 (en) 2011-02-22
ATE464564T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2005111066A3 (en) Polypeptides from non-typeable haemophilus influenzae
DK1961811T3 (da) Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
WO2006087550A3 (en) Amyloid-binding peptides, analogues and uses thereof
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
PT1171465E (pt) Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
DK2020604T3 (da) Ligand for den G-proteinkoblede receptor FPRL2
TW200616657A (en) Therapeutic peptides and method
EA200700136A1 (ru) Анти-cd154-антитела
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
WO2003093316A3 (en) Immunoglobulin-domain containing cell surface recognition molecules
DE602005020646D1 (de) Screening-verfahren
DE602004016006D1 (de) Screening-verfahren
ATE485831T1 (de) Behandlung von neurodegeneration
EP1760087A4 (de) Neuer proteinkomplex und anwendungen davon
EP1584925A4 (de) Neues screening-verfahren
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
EP1455186A4 (de) Screening-verfahren
WO2007020405A3 (en) Integrin i-domain binding peptides
WO2007068913A3 (en) SRCR-B Domain Containing Proteins
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
DE602004024300D1 (de) Anti-BAMBI Antikörper oder RNA zur Diagnose und Therapie bei Dickdarm- oder Leberkrebs
WO2003070770A3 (en) Engineered human kunitz-type protease inhibitor
EP1711604A4 (de) Diabetogene epitope

Legal Events

Date Code Title Description
8364 No opposition during term of opposition